AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

First generation EGF receptor tyrosine kinase inhibitors (EGFR TKIs) provide significant clinical benefit in patients with advanced EGFR mutant (EGFRm+) non-small cell lung cancer (NSCLC). Patients ultimately develop disease progression, often driven by acquisition of a second T790M EGFR TKI resista...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Discov
Main Authors: Cross, Darren A. E., Ashton, Susan E., Ghiorghiu, Serban, Eberlein, Cath, Nebhan, Caroline A., Spitzler, Paula J., Orme, Jonathon P., Finlay, M. Raymond V., Ward, Richard A., Mellor, Martine J., Hughes, Gareth, Rahi, Amar, Jacobs, Vivien N., Brewer, Monica Red, Ichihara, Eiki, Sun, Jing, Jin, Hailing, Ballard, Peter, Al-Kadhimi, Katherine, Rowlinson, Rachel, Klinowska, Teresa, Richmond, Graham H. P., Cantarini, Mireille, Kim, Dong-Wan, Ranson, Malcolm R., Pao, William
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4315625/
https://ncbi.nlm.nih.gov/pubmed/24893891
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-14-0337
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados